Kenneth C.  Frazier net worth and biography

Kenneth Frazier Biography and Net Worth

Insider of Merck & Co., Inc.
Kenneth C. Frazier is the Executive Chairman of Merck’s board of directors, a role he began in July 2021, following his retirement from a decade-long tenure as Merck’s President and Chief Executive Officer.   

Under Ken’s leadership, Merck delivered innovative life-saving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders.  Ken substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide far-reaching benefits to society.  He also led the formation of philanthropic and humanitarian initiatives that build on Merck’s 130-year legacy.

Ken joined the company in 1992 and held positions of increasing responsibility, including General Counsel, before becoming President and CEO in 2011.  Prior to joining Merck, Ken was a Partner with the Philadelphia law firm of Drinker Biddle & Reath.  Ken’s contributions, especially in the legal, business, and humanitarian fields, have been widely recognized.  He sits on the boards of Weill Cornell Medicine, Exxon Mobil Corporation, the National Constitution Center and Cornerstone Christian Academy in Philadelphia, PA.  He is Co-Founder and Co-Chair of OneTen, a coalition of leading organizations committed to upskilling, hiring, and promoting one million Black Americans into family-sustaining jobs.  OneTen is committed to facilitating a meaningful, measurable, and lasting impact on racial and economic justice.  Ken is also Chairman, Health Assurance Initiatives, at the venture capital firm, General Catalyst, where he advises on investments and partnerships and provides mentorship to founders building companies that are well positioned to transform the healthcare industry through collaborative and responsible innovation.  He also is a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute, the American Bar Association, and a Fellow of the College of Physicians of Philadelphia.  Additionally, Ken is Co-Chair of the Legal Services Corporation’s Leaders Council.

As a strong advocate for social justice and economic inclusion, Ken is the recipient of numerous awards and honors, including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School, the Legend in Leadership Award from the Yale School of Management, the NAACP Legal Defense and Educational Fund National Equal Justice Award, and the National Minority Quality Forum’s Lifetime Achievement Award.  In 2018, Ken received the Harvard Law School Association Award, the highest honor given by the prestigious association, in recognition of his extraordinary service to the legal profession, Harvard Law School, and the public. In that same year, Ken was named one of the World’s Greatest Leaders by Fortune magazine and was also named one of TIME’s 100 Most Influential People and again made that list in 2021.  In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare.  In 2021, Columbia Business School honored him with the Deming Cup for Operational Excellence, and his peers named Ken Chief Executive magazine’s CEO of the Year.

Ken received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.

What is Kenneth C. Frazier's net worth?

The estimated net worth of Kenneth C. Frazier is at least $67.66 million as of November 4th, 2022. Mr. Frazier owns 700,653 shares of Merck & Co., Inc. stock worth more than $67,655,054 as of November 19th. This net worth evaluation does not reflect any other assets that Mr. Frazier may own. Learn More about Kenneth C. Frazier's net worth.

How do I contact Kenneth C. Frazier?

The corporate mailing address for Mr. Frazier and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Kenneth C. Frazier's contact information.

Has Kenneth C. Frazier been buying or selling shares of Merck & Co., Inc.?

Kenneth C. Frazier has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Kenneth C. Frazier sold 235,000 shares of the business's stock in a transaction on Friday, November 4th. The shares were sold at an average price of $98.61, for a transaction totalling $23,173,350.00. Following the completion of the sale, the insider now directly owns 700,653 shares of the company's stock, valued at $69,091,392.33. Learn More on Kenneth C. Frazier's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 2/13/2024.

Kenneth C. Frazier Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2022Sell235,000$98.61$23,173,350.00700,653View SEC Filing Icon  
10/31/2022Sell300,000$100.75$30,225,000.00706,283View SEC Filing Icon  
11/9/2021Sell663,881$82.26$54,610,851.06View SEC Filing Icon  
3/20/2019Sell192,736$82.05$15,813,988.80990,451View SEC Filing Icon  
3/13/2019Sell18,725$82.00$1,535,450.00816,440View SEC Filing Icon  
3/5/2019Sell20,105$82.00$1,648,610.00810,859View SEC Filing Icon  
2/22/2019Sell53,961$80.02$4,317,959.22733,942View SEC Filing Icon  
2/19/2019Sell135,613$80.03$10,853,108.39784,863View SEC Filing Icon  
2/15/2019Sell92,913$80.03$7,435,827.39784,863View SEC Filing Icon  
2/5/2019Sell231,566$78.08$18,080,673.28923,516View SEC Filing Icon  
10/2/2018Sell279,850$72.07$20,168,789.50971,800View SEC Filing Icon  
9/18/2018Sell279,851$70.08$19,611,958.08971,801View SEC Filing Icon  
7/31/2018Sell228,091$65.00$14,825,915.00938,788View SEC Filing Icon  
11/10/2016Sell140,000$65.03$9,104,200.00514,957View SEC Filing Icon  
8/5/2016Sell392,000$61.81$24,229,520.00760,877View SEC Filing Icon  
7/5/2016Sell60,000$58.00$3,480,000.00554,856View SEC Filing Icon  
4/14/2016Sell131,040$56.11$7,352,654.40653,517View SEC Filing Icon  
10/29/2015Sell18,666$54.69$1,020,843.54438,236View SEC Filing Icon  
2/18/2015Sell5,164$58.67$302,971.88View SEC Filing Icon  
1/9/2015Sell8,840$62.47$552,234.80View SEC Filing Icon  
12/10/2014Sell9,846$60.00$590,760.00View SEC Filing Icon  
11/10/2014Sell10,000$57.98$579,800.00View SEC Filing Icon  
10/10/2014Sell9,895$59.73$591,028.35View SEC Filing Icon  
9/10/2014Sell9,814$60.48$593,550.72View SEC Filing Icon  
8/11/2014Sell10,058$57.00$573,306.00View SEC Filing Icon  
7/10/2014Sell9,987$58.03$579,545.61View SEC Filing Icon  
6/10/2014Sell9,985$58.06$579,729.10View SEC Filing Icon  
See Full Table

Kenneth C. Frazier Buying and Selling Activity at Merck & Co., Inc.

This chart shows Kenneth C Frazier's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $96.56
Low: $95.42
High: $97.29

50 Day Range

MA: $108.46
Low: $96.30
High: $118.68

2 Week Range

Now: $96.56
Low: $94.48
High: $134.63

Volume

14,139,870 shs

Average Volume

8,932,278 shs

Market Capitalization

$244.26 billion

P/E Ratio

20.24

Dividend Yield

3.13%

Beta

0.4